SHMT2 and acute lymphoblastic leukemia: In order to study the effects of SHMT1 and SHMT2 suppression after the development of T-ALL in vivo, we deployed a doxycycline-inducible shRNA system directed against SHMT1 and SHMT2 in RPMI8402.